

- c) a polypeptide having Th2-specific activity and which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:9, SEQ ID NO:11, or a complement thereof; wherein administration of the polypeptide results in modulation of the Th2 response.

21.(new) The method of claim 20, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO:10, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:10.

22.(new) The method of claim 21, wherein the fragment comprises at least 50 contiguous amino acids of SEQ ID NO:10.

23.(new) The method of claim 20, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO:12, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:12.

24.(new) The method of claim 23, wherein the fragment comprises at least 50 contiguous amino acids of SEQ ID NO:12.

25.(new) The method of claim 20, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:9 or a complement thereof under stringent conditions.

26.(new) The method of claim 20, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:11 or a complement thereof under stringent conditions.

27.(new) The method of claim 20, wherein the polypeptide is a polypeptide having Th2-specific activity and which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:9 or a complement thereof.

A2
T00211"5453660

28.(new) The method of claim 20, wherein the polypeptide is a polypeptide having Th2-specific activity and which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:11 or a complement thereof.

29.(new) The method of claim 20, wherein the Th2 response is selected from the group consisting of a Th2 dependent inflammation response, a Th2 specific effector cell response, a Th2 mediated humoral immune response, Th2 specific cytokine production, and Th2-specific ligand interaction.

30.(new) The method of claim 20, wherein the Th2 response is inducing or maintaining tolerance in autoimmune disease.

31.(new) The method of claim 20, wherein the Th2 response is inhibiting a Th1 immune response.

32.(new) The method of claim 20, wherein the polypeptide further comprises a heterologous amino acid sequence.

33.(new) The method of claim 32, wherein the heterologous amino acid sequence comprises an Ig constant region.

34.(new) The method of claim 29, wherein the Th2 specific cytokine production comprises production of a cytokine selected from the group consisting of IL-4, IL-5, IL-10, and IL-13, or a combination thereof.

35.(new) The method of claim 29, wherein the Th2 mediated humoral response comprises B cell antibody production.

36.(new) The method of claim 20, wherein the Th2 response is inhibited.

A2

0999548-11001
T002T 5456860

37.(new) The method of claim 20, wherein the Th2 response is stimulated.

38.(new) A method for modulating a Th2-mediated mucosal immune response in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a polypeptide, wherein said polypeptide is selected from the group consisting of:

- d) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:12, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:10 or SEQ ID NO:12;
- e) a polypeptide having Th2-specific activity, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:9, SEQ ID NO:11, or a complement thereof under stringent conditions; and
- f) a polypeptide having Th2-specific activity and which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:9, SEQ ID NO:11, or a complement thereof; wherein administration of the polypeptide results in modulation of the Th2-mediated mucosal immune response.

39.(new) A method for modulating a Th2-mediated altered airway response in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a polypeptide, wherein said polypeptide is selected from the group consisting of:

- g) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:12, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:10 or SEQ ID NO:12;
- h) a polypeptide having Th2-specific activity, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:9, SEQ ID NO:11, or a complement thereof under stringent conditions; and

A2

DOCKET # 4568660